Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 5:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: PO Placebo Clear all
Active, not recruiting Phase 2 Interventional

Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

NCT05111574
View directory record Official record
Conditions
Anal Melanoma, Bladder Melanoma, Cervical Melanoma, Esophageal Melanoma, Gallbladder Melanoma, Head and Neck Mucosal Melanoma, Mucosal Melanoma, Nasopharyngeal Mucosal Melanoma, Oral Cavity Mucosal Melanoma, Penile Mucosal Melanoma, Rectal Melanoma, Recurrent Mucosal Melanoma, Sinonasal Mucosal Melanoma, Urethral Melanoma, Urinary System Mucosal Melanoma, Vaginal Melanoma, Vulvar Melanoma
Interventions
Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Nivolumab, Placebo Administration, Positron Emission Tomography
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
142
States / cities
Auburn, California • Berkeley, California • Fremont, California + 116 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 24, 2026, 5:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Does Small Intestinal Bacterial Overgrowth Contribute to Functional Dyspepsia

NCT00956397
View directory record Official record
Conditions
Functional Dyspepsia, Small Intestinal Bacterial Overgrowth, Chronic Abdominal Discomfort
Interventions
Rifaximin, Lactulose Breath Test, Placebo
Drug · Procedure
Lead sponsor
Henry C. Lin, MD
Federal
Eligibility
21 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 23, 2012 · Synced Sep 24, 2026, 5:45 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Tolerability of Riluzole in Treatment Resistant Depression

NCT01204918
View directory record Official record
Conditions
Depression
Interventions
Riluzole, placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
New Haven, Connecticut • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced Sep 24, 2026, 5:45 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Treating Inflammation in Polycystic Ovary Syndrome to Ameliorate Ovarian Dysfunction

NCT03229408
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Salsalate, Placebo
Drug · Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 9, 2025 · Synced Sep 24, 2026, 5:45 PM EDT
Active, not recruiting Phase 3 Interventional Results available

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

NCT01674140
View directory record Official record
Conditions
Breast Cancer
Interventions
anastrozole, everolimus, exemestane, goserelin acetate, letrozole, leuprolide acetate, tamoxifen citrate, placebo
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
1,939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
1455
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 887 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 24, 2026, 5:45 PM EDT
Completed Phase 2 Interventional

A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection

NCT00963885
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Copegus, Pegasys, Placebo, RO5190591 (Danoprevir)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
24
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 24, 2026, 5:45 PM EDT
Recruiting Phase 3 Interventional

Opioid-Free Orthopaedics

NCT04659317
View directory record Official record
Conditions
Pain, Pain, Postoperative
Interventions
Oxycodone 5 mg Oral Tablet, Placebo oral tablet
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
3
States / cities
Atlanta, Georgia • Tucker, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 24, 2026, 5:45 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients

NCT00466440
View directory record Official record
Conditions
Prostate Cancer
Interventions
enzastaurin, placebo, docetaxel, prednisone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
22
States / cities
Fullerton, California • Los Angeles, California • Northridge, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Sep 24, 2026, 5:45 PM EDT
Completed Phase 3 Interventional Results available

Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery

NCT00326898
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Stage I Renal Cell Cancer AJCC v6 and v7, Stage II Renal Cell Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7
Interventions
Laboratory Biomarker Analysis, Placebo, Quality-of-Life Assessment, Sorafenib Tosylate, Sunitinib Malate
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1,943 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2021
U.S. locations
966
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 601 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 24, 2026, 5:45 PM EDT
Terminated Phase 2 Interventional Results available

Radiation Therapy and Capecitabine With or Without Curcumin Before Surgery in Treating Patients With Rectal Cancer

NCT00745134
View directory record Official record
Conditions
Rectal Mucinous Adenocarcinoma, Rectal Signet Ring Cell Adenocarcinoma, Recurrent Rectal Carcinoma, Stage IIA Rectal Cancer AJCC v7, Stage IIB Rectal Cancer AJCC v7, Stage IIC Rectal Cancer AJCC v7, Stage IIIA Rectal Cancer AJCC v7, Stage IIIB Rectal Cancer AJCC v7, Stage IIIC Rectal Cancer AJCC v7
Interventions
Capecitabine, Curcumin, Laboratory Biomarker Analysis, Pharmacological Study, Placebo, Quality-of-Life Assessment, Radiation Therapy
Drug · Dietary Supplement · Other + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 24, 2026, 5:45 PM EDT
Completed Phase 3 Interventional

Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery

NCT00041197
View directory record Official record
Conditions
Gastrointestinal Stromal Tumor
Interventions
imatinib mesylate, placebo, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 15, 2013 · Synced Sep 24, 2026, 5:45 PM EDT
Recruiting Phase 1Phase 2 Interventional

Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy

NCT07456852
View directory record Official record
Conditions
Malignant Digestive System Neoplasm
Interventions
Biospecimen Collection, Capecitabine, Diltiazem Hydrochloride, Electrocardiogram, Fluorouracil, Holter Monitoring, Isosorbide Mononitrate, Medical Device Usage and Evaluation, Placebo Administration, Questionnaire Administration
Procedure · Drug · Device + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 24, 2026, 5:45 PM EDT
Completed Phase 2 Interventional Results available

The Topic Trial - Study to Determine the Safety and Efficacy of Ivacaftor

NCT03085485
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis
Interventions
Ivacaftor 150 MG, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Sep 24, 2026, 5:45 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Impact of Emergency Department Probiotic (LGG) Treatment of Pediatric Gastroenteritis

NCT01773967
View directory record Official record
Conditions
Gastroenteritis
Interventions
LGG, micro-crystalline cellulose
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
3 Months to 48 Months
Enrollment
971 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
10
States / cities
Sacramento, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced Sep 24, 2026, 5:45 PM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Theophylline for Depression Study

NCT04309877
View directory record Official record
Conditions
Depression
Interventions
Theophylline ER, PO placebo, Lipopolysaccharide (LPS), IV placebo
Drug · Other · Biological
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 24, 2026, 5:45 PM EDT
Completed Phase 3 Interventional

A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

NCT03274492
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Vincristine Placebo, Prednisone, Polatuzumab vedotin Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
49
States / cities
Birmingham, Alabama • Daphne, Alabama • Duarte, California + 38 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 24, 2026, 5:45 PM EDT
Withdrawn Phase 2 Interventional

Trial Investigating the Safety and Efficacy of BRC-003 in Refractory Post-Traumatic Epilepsy

NCT06523725
View directory record Official record
Conditions
Post-traumatic Epilepsy
Interventions
PO BRC-003 (High Cannabidiol Cannabis Extract), Placebo
Drug
Lead sponsor
Dr. Paul Lyons
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Winchester, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Sep 24, 2026, 5:45 PM EDT
Withdrawn Phase 2 Interventional

Asymptomatic COVID-19 Trial

NCT04374552
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
Hydroxychloroquine sulfate &Azithromycin, Placebo
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
20 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 1, 2020 · Synced Sep 24, 2026, 5:45 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

A Study of MF101 in Postmenopausal Women

NCT00906308
View directory record Official record
Conditions
Hot Flushes, Vasomotor Symptoms
Interventions
MF101 5 g/day, Placebo, MF101 10 g/day
Drug
Lead sponsor
Bionovo
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
50
States / cities
Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 44 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2012 · Synced Sep 24, 2026, 5:45 PM EDT
Completed Phase 2 Interventional Results available

The Effect of Rivaroxaban in Sickle Cell Disease

NCT02072668
View directory record Official record
Conditions
Sickle Cell Anemia, Sickle Cell-Beta0-Thalassemia
Interventions
rivaroxaban, placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 12, 2020 · Synced Sep 24, 2026, 5:45 PM EDT
Terminated Phase 2 Interventional Results available

Statins for the Early Treatment of Sepsis

NCT00528580
View directory record Official record
Conditions
Sepsis
Interventions
Simvastatin, Identical-appearing placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Sep 24, 2026, 5:45 PM EDT
Completed Phase 1 Interventional

Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family

NCT00779389
View directory record Official record
Conditions
Head and Neck Cancer, Non Small Cell Lung Cancer
Interventions
Erlotinib, Dasatinib + Placebo, Erlotinib plus Dasatinib, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Sep 24, 2026, 5:45 PM EDT
Completed Phase 3 Interventional Results available

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

NCT01583218
View directory record Official record
Conditions
Venous Thromboembolism (VTE)
Interventions
Betrixaban, Enoxaparin
Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
7,513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
75
States / cities
Birmingham, Alabama • Bakersfield, California • Fresno, California + 69 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2023 · Synced Sep 24, 2026, 5:45 PM EDT
Terminated Phase 4 Interventional Results available

Antipsychotic Effects on Brain Function in Schizophrenia

NCT01913327
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Aripiprazole, Risperidone, Modafinil
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 40 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2020 · Synced Sep 24, 2026, 5:45 PM EDT